The Efficacy and Safety of Iron Supplementation in Patients With Heart Failure and Iron Deficiency: A Systematic Review and Meta-analysis

Canadian Journal of Cardiology

Volumn 32, Issue 2, 2016, Pages 151-159

  Qian, Cheng ^a   Wei, Baozhu ^a   Ding, Jinye ^a   Wu, Huiting ^a   Wang, Yanggan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; PLACEBO; IRON DERIVATIVE;

ALLERGIC REACTION; DEATH; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; IRON DEFICIENCY; IRON THERAPY; META ANALYSIS; MORTALITY; NEUROLOGIC DISEASE; NEW YORK HEART ASSOCIATION CLASS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VASCULAR DISEASE; ANEMIA, IRON-DEFICIENCY; BLOOD; COMPLICATION; HEALTH; NUTRITIONAL SUPPORT; ORAL DRUG ADMINISTRATION; PROCEDURES; SURVIVAL RATE;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; GLOBAL HEALTH; HEART FAILURE; HUMANS; IRON COMPOUNDS; NUTRITIONAL SUPPORT; SURVIVAL RATE;

EID: 84959178504     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.06.009     Document Type: Review

References (41)

1. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010, 31:1872-1880.
2. Klip I.T., Comin-Colet J., Voors A.A., et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013, 165:575-582.e3.
3. Beard J.L. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001, 131:568S-579S. [discussion: 580S].
4. Besarab A., Horl W.H., Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist 2009, 14(Suppl 1):22-33.
5. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011, 17:899-906.
6. Enjuanes C., Klip I.T., Bruguera J., et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol 2014, 174:268-275.
7. Rangel I., Goncalves A., de Sousa C., et al. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology 2014, 128:320-326.
8. Dunn L.L., Suryo Rahmanto Y., Richardson D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2007, 17:93-100.
9. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009, 81:412-419.
10. Swedberg K., Young J.B., Anand I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013, 368:1210-1219.
11. Moe G.W., Ezekowitz J.A., O'Meara E., et al. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol 2015, 31:3-16.
12. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000, 35:1737-1744.
13. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775-1780.
14. Comin-Colet J., Ruiz S., Cladellas M., Rizzo M., Torres A., Bruguera J. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail 2009, 15:727-735.
15. Usmanov R.I., Zueva E.B., Silverberg D.S., Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008, 21:236-242.
16. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006, 48:1225-1227.
17. Gaber R., Kotb N.A., Ghazy M., Nagy H.M., Salama M., Elhendy A. Tissue Doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy. Echocardiography 2012, 29:13-18.
18. Terrovitis J.V., Kaldara E., Ntalianis A., et al. Intravenous iron alone is equally effective with the combination of iron and erythropoietin for the treatment of iron-deficiency anemia in advanced heart failure. J Am Coll Cardiol 2012, 60:2255-2256.
19. Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
20. Higgins J.P.T., Green S. Cochrane Handbook for Systematic Reviews of Interventions 2008, xxi. Cochrane Collaboration, Wiley-Blackwell, Chichester, England/Hoboken, NJ, 649 pp.
21. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008, 51:103-112.
22. Anker S.D., Colet J.C., Filippatos G., et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009, 11:1084-1091.
23. Toblli J.E., Lombrana A., Duarte P., Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007, 50:1657-1665.
24. Arutyunov G., Bylova N., Ivleva A., Kobalava Z. The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose in patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID). Eur J Heart Fail Suppl 2009, 8. Abstract 141.
25. Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448.
26. Ponikowski P., van Veldhuisen D.J., Comin-Colet J., et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015, 36:657-668.
27. Avni T., Leibovici L., Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail 2012, 14:423-429.
28. Kapoor M., Schleinitz M.D., Gemignani A., Wu W.C. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovasc Hematol Disord Drug Targets 2013, 13:35-44.
29. Haas J.D., Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001, 131:676S-688S. [discussion: 688S-90S].
30. Blayney L., Bailey-Wood R., Jacobs A., Henderson A., Muir J. The effects of iron deficiency on the respiratory function and cytochrome content of rat heart mitochondria. Circ Res 1976, 39:744-748.
31. Willis W.T., Gohil K., Brooks G.A., Dallman P.R. Iron deficiency: improved exercise performance within 15 hours of iron treatment in rats. J Nutr 1990, 120:909-916.
32. Naito Y., Tsujino T., Matsumoto M., Sakoda T., Ohyanagi M., Masuyama T. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009, 296:H585-H593.
33. McDonagh T., Macdougall I.C. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?. Eur J Heart Fail 2015, 17:248-262.
34. Horl W.H. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007, 18:382-393.
35. Beck-da-Silva L., Piardi D., Soder S., et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013, 168:3439-3442.
36. Rozen-Zvi B., Gafter-Gvili A., Paul M., Leibovici L., Shpilberg O., Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008, 52:897-906.
37. Jankowska E.A., von Haehling S., Anker S.D., Macdougall I.C., Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013, 34:816-829.
38. Ambrosy A.P., Fonarow G.C., Butler J., et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014, 63:1123-1133.
39. Gheorghiade M., Pang P.S. Acute heart failure syndromes. J Am Coll Cardiol 2009, 53:557-573.
40. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
41. Hofmarcher T., Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ 2015, 18:492-501.